

24. (New) The polypeptide of Claim 23, wherein the polypeptide is detectably labeled.
25. (New) The polypeptide of Claim 23, wherein the polypeptide is attached to a solid substrate.
- 5 26. (New) The polypeptide of Claim 23, wherein the polypeptide is a fusion protein.
- 10 27. (New) An isolated polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or 4, or an antigenic polypeptide thereof.
28. (New) The polynucleotide of Claim 27, wherein the polynucleotide is detectably labeled.
- 15 29. (New) The polynucleotide of Claim 27, wherein the polynucleotide is a PCR product.
30. (New) An expression vector comprising the polynucleotide of Claim 27.
- 20 31. (New) A host cell comprising the expression vector of Claim 30.
32. (New) A method of producing a polypeptide of SEQ ID NO:2 or 4 comprising:
- 25 a) culturing the host cell of Claim 31 under conditions suitable for expression of the polypeptide; and
- b) isolating or purifying the polypeptide.
33. (New) An antigen binding composition which binds to a polypeptide of Claim 23.
- 30 34. (New) The antigen binding composition of Claim 33, wherein the binding composition is an Fv, Fab, or Fab2 antibody fragment.
- 35 35. (New) The antigen binding composition of Claim 33, wherein the antigen binding composition is an antibody.

36. (New) The antibody of Claim 35 wherein the antibody is:
a) a monoclonal antibody;
b) a polyclonal antibody.
- 5 37. (New) The antibody of Claim 35, wherein the antibody is attached to a solid substrate.
38. (New) The antibody of Claim 35, wherein the antibody is detectably labeled.
- 10 39. (New) A method of modulating physiology or development of a cell expressing a receptor for the polypeptide of Claim 23 comprising contacting the cell with an agonist or antagonist of the polypeptide.
- 15 40. (New) The method of Claim 39, wherein the cell is a macrophage or a lymphocyte.
41. (New) The method of Claim 39, wherein the antagonist is an antibody which binds to the polypeptide.
- 20 42. (New) The method of Claim 39, wherein the physiology is selected from the group consisting of:
a) a cellular calcium flux;
b) a chemoattractant response;
25 c) cellular morphology modification responses;
d) phosphoinositide lipid turnover; and
e) an antiviral response.

REMARKS

- 30 Applicants cancel originally filed Claims 1-22, without prejudice. New claims 23-42 are added. Support for new Claims 23-26 can be found in originally filed Claim 3. New Claims 27-32 are supported by originally filed Claims 4-6. Support for new Claims 33-38 can be found in originally filed Claim 15. Support for new Claims 39-42 can be found in originally filed Claims 19-21. Applicants
- 35 believe that no new matter is added by the above amendments. Entry of the above amendment is therefore respectfully requested.